Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y.
The hypothalamic neuropeptide Y content and preproneuropeptide Y mRNA expression were studied in metformin-treated (300 mg/kg orally for 12 days), in pair-fed and in ad libitum-fed obese Zucker rats in order to elucidate possible mechanisms involved in the anorectic and body weight reducing effect of chronic metformin treatment in genetically obese Zucker rats. In addition the acute influence of metformin on food intake was studied by comparing its effects after oral and parenteral administration. The concentration of neuropeptide Y in the hypothalamic paraventricular nucleus was significantly higher in the metformin-treated and pair-fed rats when compared to the control animals. The expression of preproneuropeptide Y mRNA in the arcuate nucleus was similar in all three treatment groups. Both chronic metformin treatment and pair-feeding markedly lowered hyperinsulinaemia in these animals. A single subcutaneous dose of metformin (300 mg/kg) reduced food intake only in obese animals, while the same dose of metformin given orally did not affect food intake in either lean or obese animals. It is concluded that the treatment with metformin and pair-feeding, which results in comparable reductions in food intake, body weight gain and hyperinsulinaemia, similarly increase neuropeptide Y concentrations in the paraventricular nucleus while not affecting preproneuropeptide Y mRNA expression in the arcuate nucleus. The increase in hypothalamic neuropeptide Y content may be secondary to the reduction in hyperinsulinaemia during metformin treatment and pair-feeding. Thus, the anorectic effect of chronic metformin treatment cannot be explained by changes in content or expression of hypothalamic neuropeptide Y.
Rouru
J
J
Department of Pharmacology, University of Turku, Finland.
Pesonen
U
U
Koulu
M
M
Huupponen
R
R
Santti
E
E
Virtanen
K
K
Rouvari
T
T
Jhanwar-Uniyal
M
M
D000284:Administration, Oral; D000818:Animals; D001067:Appetite Depressants / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D009765:Obesity / Q000235:genetics / Q000523:psychology*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011924:Rats, Zucker
D001067:Appetite Depressants; D001786:Blood Glucose; D007328:Insulin; D009478:Neuropeptide Y; D012333:RNA, Messenger; D008687:Metformin